Background This register-based observational study compares dabigatran to warfarin for
secondary stroke prevention in atrial fibrillation patients among both “new starters” on …

Background and Purpose—Little is known about the clinical outcomes associated with
posthemorrhage anticoagulation resumption for atrial fibrillation. This study had 2 objectives …

Randomised clinical trials are presently the most objective tool for assessment of an
intervention, such as drug treatment or prevention effects, but the results may not necessarily …

Background and purpose GLORIA-AF is a large, global, prospective registry program of
newly diagnosed atrial fibrillation (AF) patients with≥ 1 stroke risk factors. We describe the …

The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

Background—Dabigatran 150 and 110 mg twice a day and warfarin are effective for stroke
prevention in atrial fibrillation. The purpose of this study was to compare their risks of …

Model I predicts the observed pre-dose means adequately, but tends to overpredict the
peak. Model II tends to underpredict the pre-dose means, but adequately describes the …

Background Dabigatran may provide less protection against myocardial infarction than
vitamin K antagonists (VKAs) in patients with atrial fibrillation. This may be particularly …

Background—Trial data for the benefits and risks of dabigatran versus warfarin in the
treatment of nonvalvular atrial fibrillation are lacking. We sought to review real-world …

The effectiveness and safety of dabigatran for stroke prevention in atrial fibrillation (SPAF)
demonstrated in RE-LY needs to be confirmed in daily care. To evaluate treatment …